1. Scrip
  2. >>Therapy Areas

CSL’s High Hopes For Heart Attack Therapy Come Crashing Down

 
• By Kevin Grogan

The Australian firm has reported disappointing results from an 18,200-patient trial of its plasma-derived apolipoprotein A-I therapy which did not cut the risk of major adverse cardiovascular events following acute myocardial infarction.

CSL HQ
• Source: CSL

CSL Limited's stock has taken a big hit following the failure of the biggest trial in the Australian major's history for a closely watched heart attack therapy.

The Melbourne-headquartered company has announced top-line results from the Phase III AEGIS-II trial evaluating CSL112 (plasma-derived apolipoprotein A-I [apoA-I]) in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.